Recent Price Movement and Market Context
On 16 Dec 2025, Mankind Pharma’s stock price declined by 1.60%, underperforming its Pharmaceuticals & Biotechnology sector by 1.31%. This marks the second consecutive day of losses, with the stock returning -3.47% over this period. The new 52-week low of Rs.2103.05 contrasts sharply with its 52-week high of Rs.3050, highlighting a notable contraction in valuation over the past year.
The broader market environment has also been challenging. The Sensex opened 187.75 points lower and closed down by 315.09 points at 84,710.52, a 0.59% decline. Despite this, the Sensex remains 1.71% below its own 52-week high of 86,159.02 and continues to trade above its 50-day moving average, signalling relative resilience compared to Mankind Pharma’s share price trajectory.
Technical Indicators Reflect Bearish Sentiment
Mankind Pharma is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This broad-based weakness across short, medium, and long-term technical indicators suggests persistent selling pressure. The stock’s inability to sustain levels above these averages indicates a cautious market stance towards the company’s near-term prospects.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Financial Performance and Valuation Metrics
Over the last twelve months, Mankind Pharma’s stock has delivered a return of -21.55%, contrasting with the Sensex’s positive 3.60% return over the same period. This underperformance is mirrored in the company’s profit figures, with reported profits declining by approximately 17.2% year-on-year.
The company’s latest half-yearly profit after tax (PAT) stands at Rs.949.83 crores, reflecting a contraction of 20.05% compared to the previous period. Interest expenses for the nine months reached Rs.530.87 crores, representing a growth of 122.24%, which may be indicative of increased borrowing costs or higher debt levels.
Return on Capital Employed (ROCE) for the half year is recorded at 12.33%, with a recent figure of 11.7% noted alongside an enterprise value to capital employed ratio of 4.6. These figures suggest a relatively elevated valuation compared to historical peer averages, despite the subdued profit growth.
Long-Term and Sectoral Performance
Mankind Pharma’s performance over the longer term also reflects challenges. The stock has underperformed the BSE500 index across multiple time frames, including the last three years, one year, and three months. This trend points to persistent pressures relative to the broader market and sector peers.
Despite these headwinds, the company maintains a high management efficiency level, with a reported ROCE of 25.78% in certain assessments. Additionally, the firm’s debt servicing capacity remains strong, supported by a low Debt to EBITDA ratio of 0.54 times, indicating manageable leverage levels.
Institutional Holdings and Market Position
Institutional investors hold approximately 24.76% of Mankind Pharma’s shares. This level of institutional participation suggests a degree of confidence in the company’s fundamentals from entities with extensive analytical resources. However, this has not translated into immediate price support amid current market conditions.
Why settle for Mankind Pharma ? SwitchER evaluates this Pharmaceuticals & Biotechnology large-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Summary of Key Concerns
The stock’s decline to Rs.2103.05, its lowest level in a year, reflects a combination of subdued profit growth, rising interest expenses, and valuation metrics that appear elevated relative to peers. The persistent trading below all major moving averages further underscores the cautious sentiment prevailing among market participants.
While the broader market, as represented by the Sensex, maintains a more positive technical stance, Mankind Pharma’s share price trajectory has diverged, highlighting company-specific pressures within the Pharmaceuticals & Biotechnology sector.
Market Outlook and Considerations
Investors and market watchers will likely continue to monitor Mankind Pharma’s financial disclosures and sector developments closely. The company’s ability to manage costs, sustain profitability, and align valuation with fundamentals will remain key focal points in assessing its market performance going forward.
Conclusion
Mankind Pharma’s stock reaching a 52-week low of Rs.2103.05 marks a significant milestone in its recent market journey. The combination of financial metrics, technical indicators, and sector dynamics provides a comprehensive picture of the factors influencing this price movement. While the stock faces challenges relative to its historical highs and sector benchmarks, the detailed data offers a clear view of its current standing within the Pharmaceuticals & Biotechnology industry.
Only for Rs. 14,999 - Get Access to 2 Years + 6 Months of All Premium Features on MarketsMojo. As low as ₹500/month! Claim 83% OFF →
